Patents Represented by Attorney Isis Patent Department Woodcock Washburn LLP
-
Patent number: 7884086Abstract: The present invention provides methods of identifying oligomeric compounds, such as siRNA and double-stranded RNA compounds, having bioactivity in vivo, and kits.Type: GrantFiled: September 7, 2005Date of Patent: February 8, 2011Assignee: Isis Pharmaceuticals, Inc.Inventors: C. Frank Bennett, Robert McKay, Brett P. Monia, Brenda F. Baker, Namir Sioufi
-
Patent number: 7125975Abstract: Linked nucleosides having at least one functionalized nucleoside that bears a substituent such as a steroid molecule, a reporter molecule, a non-aromatic lipophilic molecule, a reporter enzyme, a peptide, a protein, a water soluble vitamin, a lipid soluble vitamin, an RNA cleaving complex, a metal chelator, a porphyrin, an alkylator, a pyrene, a hybrid photonuclease/intercalator, or an aryl azide photo-crosslinking agent exhibit increased cellular uptake and other properties. The substituent can be attached at the 2?-position of the functionalized nucleoside via a linking group. If at least a portion of the remaining liked nucleosides are 2?-deoxy-2?-fluoro, 2?-O-methoxy, 2?-O-ethoxy, 2?-O-propoxy, 2?-O-aminoalkoxy or 2?-O-allyloxy nucleosides, the substituent can be attached via a linking group at any of the 3? or the 5? positions of the nucleoside or on the heterocyclic base of the nucleoside or on the inter-nucleotide linkage linking the nucleoside to an adjacent nucleoside.Type: GrantFiled: January 9, 2004Date of Patent: October 24, 2006Assignee: Isis Pharmaceuticals, Inc.Inventors: Muthiah Manoharan, Phillip Dan Cook, Clarence Frank Bennett
-
Patent number: 7119184Abstract: Modified oligonucleotides containing both A-form conformation geometry and B-from conformation geometry nucleotides are disclosed. The B-form geometry allows the oligonucleotide to serve as substrates for RNase H when bound to a target nucleic acid strand. The A-form geometry imparts properties to the oligonucleotide that modulate binding affinity and nuclease resistance. By utilizing C2? endo sugars or O4? endo sugars, the B-form characteristics are imparted to a portion of the oligonucleotide. The A-form characteristics are imparted via use of either 2?-O-modified nucleotides that have 3? endo geometries or use of end caps having particular nuclease stability or by use of both of these in conjunction with each other.Type: GrantFiled: October 4, 2001Date of Patent: October 10, 2006Assignee: Isis Pharmaceuticals, Inc.Inventors: Muthiah Manoharan, Venkatraman Mohan, Phillip Dan Cook, Andrew M. Kawasaki
-
Patent number: 7101993Abstract: Compounds are provided containing purine nucleotides that bear moieties X at the 2? position thereof wherein X is R1—(R2)n; R1 is C3-C20 alkyl, C4-C20 alkenyl or C2-C20 alkynyl; R2 is halogen, hydroxyl, thiol, keto, carboxyl, nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, O-alkyl, S-alkyl, NH-alkyl, N-dialkyl, O-aryl, S-aryl, NH-aryl, O-aralkyl, S-aralkyl, NH-aralkyl, amino, N-phthalimido, imidazole, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, aryl, heterocycle, carbocycle, intercalator, reporter molecule, conjugate, polyamine, polyamide, polyalkylene glycol, polyether, a group that enhances the pharmacodynamic properties of oligonucleotides, or a group that enhances the pharmacokinetic properties of oligonucleotides; and n is an integer from 0 to about 6. Such compounds are useful for modulating the synthesis of proteins.Type: GrantFiled: October 27, 1992Date of Patent: September 5, 2006Assignee: ISIS Pharmaceuticals, Inc.Inventors: Phillip Dan Cook, Daniel Peter Claude McGee, Charles John Guinosso
-
Patent number: 7038037Abstract: A sequential support-bound synthesis method is disclosed for preparing a conjugated oligomeric compound, preferably a PNA-peptide conjugate or an oligonucleotide-peptide conjugate, using a bridging molecule having at least two N-protecting amino groups. A conjugated oligomeric compound for therapeutic or prophylactic delivery is also disclosed.Type: GrantFiled: June 20, 2002Date of Patent: May 2, 2006Assignee: ISIS Pharmaceuticals, Inc.Inventors: Martin A. Maier, Andrei P. Guzaev, Muthiah Manoharan
-
Patent number: 7030230Abstract: A process of purifying phosphoramidite precursors useful in inter alia synthesis of oligonucleotides comprises dissolving a crude phosphoramidite in a polar phase, adding a basic compound to the polar phase, adding a portion of water to the polar phase, contacting the polar phase with a first apolar phase to extract impurity into the apolar phase, separating the first apolar phase from the polar phase, adding a second aliquot of water to the polar phase, and contacting the polar phase with a second apolar phase, whereby the phosphoramidite partitions into the second apolar phase.Type: GrantFiled: October 25, 2002Date of Patent: April 18, 2006Assignee: ISIS Pharmaceuticals, Inc.Inventors: Bruce Ross, Quanlai Song
-
Patent number: 6967242Abstract: The present invention is directed to analogs of aminoglycoside compounds of the class having a glycosylated 2-deoxystreptamine (2-DOS) ring as well as their preparation and use as prophylactic or therapeutics against microbial infection. Compounds of the invention comprises at least one aryl, heteroaryl, substituted aryl or substituted heteroaryl group in place of a glycosyl group attached to the 2-deoxystreptamine ring.Type: GrantFiled: November 19, 2002Date of Patent: November 22, 2005Assignee: ISIS Pharmaceuticals, Inc.Inventors: Eric Swayze, Richard H. Griffey, Yili Ding, Venkatraman Mohan
-
Patent number: 6967247Abstract: A process for removing a phosphorus protecting group from a protected phosphate triester or phosphorothioate triester includes contacting a protected phosphate or phosphorothioate triester with a thiol compound that is not offensive to the olfactory senses.Type: GrantFiled: July 24, 2002Date of Patent: November 22, 2005Assignee: ISIS Pharmaceuticals, Inc.Inventor: Vasulinga Ravikumar
-
Patent number: 6919439Abstract: Linked nucleosides having at least one functionalized nucleosid that bears a substituent such as a steroid molecule, a reporter molecule, a non-aromatic lipophilic molecule, a reporter enzyme, a peptide, a protein, a water soluble vitamin, lipid soluble vitamin, an RNA cleaving complex, a metal chelator, a porphyrin, an alkylator, a pyrene, a hybrid photonuclease/intercalator, or an aryl azide photo-crosslinking agent exhibit increased cellular uptake and other properties. The substituent can be attached at the 2?-position of the functionalized nucleoside via a linking group. If at least a portion of the remaining linked nucleosides are 2?-deoxy-2?-fluoro, 2?-O-methoxy, 2?-O-ethoxy, 2?-O-propoxy, 2?-O-aminoalkoxy or 2?-O-allyloxy nucleosides, the substituent can be attached via a linking group at any of the 3? or the 5? positions of the nucleoside or on the heterocyclic base of the nucleoside or on the inter-nucleotide linkage linking the nucleoside to an adjacent nucleoside.Type: GrantFiled: May 23, 2002Date of Patent: July 19, 2005Assignee: ISIS Pharmaceuticals, Inc.Inventors: Muthiah Manoharan, Phillip Dan Cook, Clarence Frank Bennett
-
Patent number: 6919437Abstract: Methods for the preparation of oligonucleotides having bioreversible phosphate blocking groups are disclosed. In one aspect, the present invention provides compounds comprising a sequence of nucleotide units that includes a first segment having at least one internucleoside linkage of formula: 3?-O—P(X)(O?)—O-5? and a second segment having at least one internucleoside linkage of formula: 3?-O—P(X)(Y1—(CH2)q—Y2—Y3—Z)—O-5? wherein each of X, Y1, and Y2 is, independently, O or S; q is 2 to about 4; Y3 is C(?O) or S; and Z is aryl having 6 to about 14 carbon atoms or alkyl having from one to about six carbon atoms.Type: GrantFiled: June 10, 1999Date of Patent: July 19, 2005Assignee: ISIS Pharmaceuticals, Inc.Inventors: Muthiah Manoharan, Andrei Guzaev
-
Patent number: 6911540Abstract: Oligomers which have substituents on the 2? position are resistant to oligonucleases and furthermore can be derivatized to deliver reagents or drugs, to carry label, or to provide other properties.Type: GrantFiled: June 27, 2002Date of Patent: June 28, 2005Assignee: ISIS Pharmaceuticals, Inc.Inventors: Chris A. Buhr, Mark Matteucci
-
Patent number: RE39324Abstract: Compounds having structure (1) wherein R1 is —H a protecting group, a linker or a binding partner; and R2 and R34 are as defined in the specification. The invention also provides intermediates and methods make the structure (1) compounds, as well as methods to use the compounds as labels in diagnostic assays and to enhance binding to complementary bases.Type: GrantFiled: February 21, 2002Date of Patent: October 3, 2006Assignee: ISIS Pharmaceuticals, Inc.Inventors: Kuei-Ying Lin, Mark D. Matteucci
-
Patent number: RE39464Abstract: Novel chiral compounds that mimic and/or modulate the activity of wild-type nucleic acids are disclosed. In general, the compounds are phosphorothioate oligonucleotides wherein the 5?, and the 3?-terminal internucleoside linkages are chirally Sp and internal internucleoside linkages are chirally Rp.Type: GrantFiled: August 24, 2004Date of Patent: January 9, 2007Assignee: ISIS Pharmaceuticals Inc.Inventors: Phillip Dan Cook, Muthiah Manoharan